tirzepatide cancer Scientists have discovered that tirzepatide—an FDA-approved drug for diabetes and weight loss (Mounjaro, Zepbound)—can also shrink breast tumors in obese mice. Presented at ENDO 2025, the University of Michigan study showed Tirzepatide and Thyroid Cancer: UK

Safety Considerations Common Side Effects Nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal pain Injection site reactions (redness, itching, swelling) Hypoglycemia (especially if used with insulin or sulfonylureas) Serious Risks Pancreatitis: Seek immediate medical attention for severe abdominal pain

Drinking adequate water throughout the day benefits both digestion and general health during Zepbound treatment

Book an appointment and take the first step toward better health

Daniel Drucker, a professor and researcher at the University of Torontos Mount Sinai Hospital and a pioneer of research into GLP-1

Real humans answer questions

Weve found that most discomfort occurs because the body is learning to process smaller volumes of food at a much slower pace